If you saw a Palatin headline and are asking what an anti-obesity peptide is, here is the short version. The phrase covers three different things: approved GLP-1 medicines, macrocyclic peptides used in drug discovery, and MC4R peptides from Palatin that are still early. Palatin's peptides are preclinical, the evidence it cites comes from obese mice, and its first human trial is targeted for the first half of 2027. As of November 9, 2026, no human data on its lead peptide had been reported. Separately, on November 9, 2026, the FDA required an eye-risk warning for all GLP-1 medicines.
Paid placement disclosure: The Palatin article is a paid placement. Palatin is a paid subscriber to Wall Street Wire's Market Discovery Program, the coverage is not independent, it is not investment advice, and it is not a communication from the company itself.
What is an anti-obesity peptide?
Headlines lump three groups together. They are different things at different stages, so keep them apart.
| Group | What it is | Stage as of November 9, 2026 |
|---|---|---|
| GLP-1 receptor agonists (GLP-1 RAs) | FDA-approved injectable and oral medicines. FDA lists the class for reducing excess body weight and maintaining weight reduction, among other uses. | Approved. FDA required new NAION eye-risk labeling for all GLP-1 RA medications on November 9, 2026. |
| Macrocyclic peptides | A drug-discovery platform. BioPharma Dive describes them as larger and more complex than typical small molecules, able to bind hard-to-drug targets, yet small enough to be swallowed. | argenx announced on November 9, 2026 that it will acquire Unnatural Products, which works on them. As of November 9, 2026, no clinical data on any UNP drug had been reported. |
| MC4R peptides | Palatin's next-generation peptides that target the melanocortin-4 receptor (MC4R). The Palatin article says MC4R helps regulate hunger and energy balance. | Preclinical. The Palatin article says the next step is IND-enabling studies, with Phase 1 targeted for the first half of 2027. |
The FDA warning covers GLP-1 RA medicines. It does not name Palatin's peptides, which are not approved.
Common mix-ups to avoid
- The eye warning is for GLP-1 medicines only. FDA's labeling change names GLP-1 RA medications. It does not name Palatin's peptides.
- Imcivree is an approved medicine, not one of Palatin's new peptides. The Palatin article says Imcivree is approved for acquired hypothalamic obesity in the US, EU, UK and Japan. BioPharma Dive lists it among earlier macrocyclic-peptide approvals.
- Bremelanotide (Vyleesi) is Palatin's earlier, approved drug. The Palatin article says FDA approved it in 2019 for hypoactive sexual desire disorder, not for obesity.
- The argenx deal is not an MC4R deal. It concerns macrocyclic peptides aimed at serious immune-mediated diseases.
What is the MC4R pathway?
MC4R is a receptor in the brain. The Palatin article says it helps regulate hunger and energy balance. A 2014 rat study of an engineered MC4R agonist, AST3-88, found that when it was given centrally, the rats' food intake decreased (AST3-88 MC4R study in rats). A separate 2025 rat study in the journal Nutrients found that blocking brain MC4R reduced the effect of GLP-2 on gut lipid output; it does not address hunger (2025 Nutrients study on MC4R).
What does Imcivree already do there?
Imcivree is made by Rhythm Pharmaceuticals. The Palatin article says it is approved for acquired hypothalamic obesity in the US, EU, UK and Japan. BioPharma Dive describes its approval differently: FDA approved it in 2020 for certain genetic forms of obesity. Because the two descriptions differ, ask your prescriber to confirm the approved use on the current label. For Palatin's own peptides, the initial targets are acquired hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome. The Palatin article is a paid placement.
What are Palatin's new peptides meant to improve?
The Palatin article says the company's two new peptide series potently activate MC4R with no detectable MC1R activity. MC1R matters for skin pigmentation. The article also says GI side effects and hyperpigmentation, meaning skin darkening, remain challenges for this category. Palatin's CEO, Carl Spana, has said MC4R agonism is “clinically and commercially validated.” On dosing, Palatin says early pharmacokinetic data support once-weekly or less frequent dosing in humans. That is a company statement. The Palatin article is a paid placement.
What is the evidence so far?
So far the data come from animals. Palatin says its lead program, a lipidated peptide from the PL2000 series, cut food intake and body weight with once-weekly dosing in obese mice. The next step is IND-enabling studies. Phase 1 is targeted for the first half of 2027, with initial data targeted for the second half of 2027. As of November 9, 2026, no human data on the lead peptide had been reported. Palatin also has an oral small-molecule MC4R program and early preclinical work on an oral peptide. The Palatin article is a paid placement.
Palatin's earlier drug, bremelanotide (Vyleesi), was studied in a 2025 Phase 2 obesity study with tirzepatide. Palatin reports that 40% reached at least 5% weight loss, compared with 27% on tirzepatide alone. That is a company-reported result from a different combination than the MC4R peptides.
What is the going-concern disclosure?
The Palatin article is a paid placement. It says Palatin has disclosed going-concern uncertainty and will need additional funding. A going-concern disclosure is a company's own statement that there is doubt it can keep operating without new money. This page does not weigh whether Palatin or its shares are worth buying.
What happened with argenx and macrocyclic peptides?
On November 9, 2026, argenx (Euronext and Nasdaq: ARGX) announced a definitive agreement to acquire Unnatural Products, Inc., a Santa Cruz, California company. argenx already holds a minority stake and will buy the rest. argenx press release on the acquisition lists $550 million upfront in cash on hand, plus up to $595 million contingent on specified development and regulatory milestones, for total potential consideration of up to about $1.15 billion. The deal is expected to close by the end of 2026, subject to customary closing conditions. argenx plans to use the platform for oral or long-acting medicines for serious immune-mediated diseases. As of November 9, 2026, no clinical data on any UNP drug had been reported.
Who does this affect?
- People taking a GLP-1 medicine. The FDA labeling change is about NAION, a rare eye condition. Details are below.
- People with the conditions Palatin names. Its initial targets are acquired hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome. Its peptides are still early, so there is no Palatin peptide to weigh as an option yet.
What did the FDA say about GLP-1 medicines and eye risk?
The FDA's FDA drug safety communication on GLP-1 eye risk, published November 9, 2026, says FDA is requiring all GLP-1 RA medications to add information about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) to the Warnings and Precautions section of the label. FDA describes NAION as a rare condition that can cause acute, painless decreased vision in one eye, including permanent vision loss.
FDA lists these symptoms: sudden, painless vision loss in one eye that you may notice when you wake up, blurred or missing parts of vision, distorted colors, and reduced central sharpness. Contact a health care professional right away if you notice any of these. FDA says NAION risk factors may include smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. If NAION has occurred in one eye, there is an increased risk it will occur in the other eye. If you have had a NAION event, FDA says to talk with your health care professional about whether to continue or stop the GLP-1 RA.
| Comparison | What FDA reports |
|---|---|
| Meta-analysis of 126 randomized controlled trials (134,253 patients) | 6.4 probable NAION events per 100,000 person-years on GLP-1 RAs vs 3.8 per 100,000 on comparators |
| FDA Sentinel cohort of adults with type 2 diabetes: GLP-1 RAs vs DPP-4 inhibitors | Hazard ratio 1.43 (95% CI 1.02 to 2.01) |
| FDA Sentinel cohort: GLP-1 RAs vs SGLT-2 inhibitors | Hazard ratio 1.19 (95% CI 0.91 to 1.54), not statistically significant |
| General population, adults older than 50 (published incidence FDA cites) | 2.3 to 10.2 per 100,000 persons per year |
Key dates
| Date | What happened | Source |
|---|---|---|
| July 2024 | A JAMA Ophthalmology study of semaglutide (Hathaway et al.) prompted FDA's full review of GLP-1 RA eye risk | FDA, November 9, 2026 |
| 2019 | FDA approved bremelanotide (Vyleesi) for hypoactive sexual desire disorder | Palatin article (paid placement), November 9, 2026 |
| 2020 | FDA approved Imcivree for certain genetic forms of obesity | BioPharma Dive, November 9, 2026 |
| November 9, 2026 | FDA labeling change for GLP-1 RA medications; argenx announces the Unnatural Products deal | FDA; argenx press release |
| End of 2026 | argenx deal expected to close, subject to customary closing conditions | argenx press release |
| First half of 2027 | Palatin Phase 1 start targeted | Palatin article (paid placement), November 9, 2026 |
| Second half of 2027 | Palatin initial data targeted | Palatin article (paid placement), November 9, 2026 |
Questions to settle your next step
- Do you take a GLP-1 medicine and have you noticed sudden, painless vision changes in one eye? Contact a health care professional right away.
- If you have had a NAION event, ask your prescriber whether to continue or stop your GLP-1 medicine. Do not change it on your own.
- For vision changes, see an eye doctor: an optometrist or ophthalmologist.
- Ask your pharmacist whether any medicine you are considering is FDA-approved, and what its label says.
- To report a problem, use FDA MedWatch online or call 1-800-332-1088.
For prescription questions, see our peptide prescription guide. For side effects and how to report them, read peptide adverse reaction help.
By SterlingMedicalCenter.org Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.
Read next